Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 226 results
Filters: Author is Rosenkranz, Susan L  [Clear All Filters]
Found 226 results.

Adult

Asmuth DM, Murphy RL, Rosenkranz SL, et al. "Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial." J. Infect. Dis.. 2010;201(11):1686-96.
Aweeka FT, Rosenkranz SL, Segal Y, et al. "The impact of sex and contraceptive therapy on the plasma and intracellular pharmacokinetics of zidovudine." AIDS. 2006;20(14):1833-41.
Gupta SK, Rosenkranz SL, Cramer YS, et al. "The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis." AIDS. 2008;22(15):1919-27.
Andrade A, Rosenkranz SL, Cillo AR, et al. "Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248." J. Infect. Dis.. 2013;208(6):884-91.
Ma Q, Forrest A, Rosenkranz SL, et al. "Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers." Biopharm Drug Dispos. 2008;29(2):91-101.
Aberg JA, Rosenkranz SL, Fichtenbaum CJ, et al. "Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108." AIDS. 2006;20(5):725-9.
Luetkemeyer AF, Rosenkranz SL, Lu D, et al. "Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study." Clin. Infect. Dis.. 2013;57(4):586-93.
Para MF, Schouten J, Rosenkranz SL, et al. "Phase I/II trial of the anti-HIV activity of mifepristone in HIV-infected subjects ACTG 5200." J. Acquir. Immune Defic. Syndr.. 2010;53(4):491-5.
Funderburg NT, Andrade A, Chan ES, et al. "Dynamics of immune reconstitution and activation markers in HIV+ treatment-naïve patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabine." PLoS ONE. 2013;8(12):e83514.

Anti-HIV Agents

Gupta SK, Rosenkranz SL, Cramer YS, et al. "The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis." AIDS. 2008;22(15):1919-27.
Luetkemeyer AF, Rosenkranz SL, Lu D, et al. "Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study." Clin. Infect. Dis.. 2013;57(4):586-93.
Andrade A, Rosenkranz SL, Cillo AR, et al. "Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248." J. Infect. Dis.. 2013;208(6):884-91.
Asmuth DM, Murphy RL, Rosenkranz SL, et al. "Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial." J. Infect. Dis.. 2010;201(11):1686-96.
Cramer YS, Rosenkranz SL, Hall SD, Szczech LA, Amorosa V, Gupta SK. "Hemodialysis does not significantly affect the pharmacokinetics of nevirapine in HIV-1-infected persons requiring hemodialysis: results from ACTG A5177." J. Acquir. Immune Defic. Syndr.. 2010;54(4):e7-9.
Para MF, Schouten J, Rosenkranz SL, et al. "Phase I/II trial of the anti-HIV activity of mifepristone in HIV-infected subjects ACTG 5200." J. Acquir. Immune Defic. Syndr.. 2010;53(4):491-5.
Funderburg NT, Andrade A, Chan ES, et al. "Dynamics of immune reconstitution and activation markers in HIV+ treatment-naïve patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabine." PLoS ONE. 2013;8(12):e83514.
Bakshi RP, Hamzeh F, Frank I, et al. "Effect of hydroxyurea and dideoxyinosine on intracellular 3'-deoxyadenosine-5'-triphosphate concentrations in HIV-infected patients." AIDS Res. Hum. Retroviruses. 2007;23(11):1360-5.

Pages